Mupirocin calcium

DRUG2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Padagis LLC

Conditions

Secondarily Infected Traumatic Skin LesionsStaphylococcal Infection

Phase 2

Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants

CompletedNCT01827358

National Institute of Allergy and Infectious Diseases (NIAID)Staphylococcal Infection

Start: 2014-04-30End: 2016-06-21Updated: 2017-07-07

Phase 3

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions

CompletedNCT04155203

Padagis LLCSecondarily Infected Traumatic Skin Lesions

Start: 2019-10-15End: 2021-06-01Updated: 2022-11-03